Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease
- PMID: 1683085
- DOI: 10.1530/acta.0.1250253
Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease
Abstract
We measured soluble interleukin 2 receptor, a part of the Tac protein (p55), in peripheral blood to study the immunological condition of the T cell in autoimmune thyroid disease. In 26 patients with untreated Graves' disease and 7 hyperthyroid patients with Hashimoto's thyroiditis, the mean levels of soluble IL-2 receptor were both significantly higher than in normal controls (1497 +/- 649 (mean +/- SD), 641 +/- 137 vs 221 +/- 63 10(3) U/l, p less than 0.001). There was good correlation between soluble IL-2 receptor levels and blood thyroxine levels (r = 0.684, p less than 0.001) in patients with untreated Graves' disease, but no correlation of soluble IL-2 receptor with TSH-inhibitory immunoglobulins, TS-ab, thyroidal autoantibodies to thyroglobulin and thyroidal microsomal antigen was found. We thought that the level of soluble IL-2 receptor is not dependent only on immunological conditions, but also on thyroid hormone status. When T3 was administered to subjects in remission from Graves' disease and in normal controls, the soluble IL-2 receptor levels significantly increased. Moreover, the mean level of soluble IL-2 receptor in patients with toxic multinodular goitre was also significantly higher than in normal controls (411 +/- 148 vs 221 +/- 63 10(3)U/l, p less than 0.05). We conclude that the soluble IL-2 receptor levels are higher in sera of subjects with elevated levels of thyroid hormone.
Similar articles
-
In vitro production of interferon-gamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis.Clin Exp Immunol. 1990 Oct;82(1):63-8. doi: 10.1111/j.1365-2249.1990.tb05404.x. Clin Exp Immunol. 1990. PMID: 1976464 Free PMC article.
-
Soluble interleukin-2 receptor in sera of patients with Graves' disease.Acta Med Hung. 1991;48(1-2):3-11. Acta Med Hung. 1991. PMID: 1813855
-
The thyroid "microsomal" antigen is an epitope on the thyrotropin receptor.J Cell Biochem. 1986;31(2):107-20. doi: 10.1002/jcb.240310204. J Cell Biochem. 1986. PMID: 2426288
-
Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.J Clin Endocrinol Metab. 1995 Jul;80(7):2173-7. doi: 10.1210/jcem.80.7.7608274. J Clin Endocrinol Metab. 1995. PMID: 7608274
-
TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.Exp Clin Endocrinol Diabetes. 2004 Apr;112(4):171-4. doi: 10.1055/s-2004-817930. Exp Clin Endocrinol Diabetes. 2004. PMID: 15127319 Review.
Cited by
-
Serum levels of interleukin-12 in Graves' disease and their dynamic changes after surgery.Surg Today. 2005;35(12):1016-20. doi: 10.1007/s00595-005-3083-7. Surg Today. 2005. PMID: 16341480
-
Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.Clin Diagn Lab Immunol. 1997 Sep;4(5):583-6. doi: 10.1128/cdli.4.5.583-586.1997. Clin Diagn Lab Immunol. 1997. PMID: 9302209 Free PMC article. Clinical Trial.
-
Serum-soluble interleukin-2 receptor levels before and after surgical treatment for Graves' disease.Surg Today. 1995;25(1):55-8. doi: 10.1007/BF00309386. Surg Today. 1995. PMID: 7538365
-
Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.J Endocrinol Invest. 1994 Dec;17(11):861-7. doi: 10.1007/BF03347792. J Endocrinol Invest. 1994. PMID: 7745234
-
Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.Jpn J Cancer Res. 1998 Apr;89(4):436-44. doi: 10.1111/j.1349-7006.1998.tb00582.x. Jpn J Cancer Res. 1998. PMID: 9617350 Free PMC article.